These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement. Ross AH; Jaycock P; Cook SD; Dick AD; Tole DM Br J Ophthalmol; 2009 Apr; 93(4):421-2, 548. PubMed ID: 19321473 [No Abstract] [Full Text] [Related]
4. Sustained clinical response to rituximab in a case of life-threatening overlap subepidermal autoimmune blistering disease. Li Y; Foshee JB; Sontheimer RD J Am Acad Dermatol; 2011 Apr; 64(4):773-8. PubMed ID: 20494477 [TBL] [Abstract][Full Text] [Related]
5. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. Lourari S; Herve C; Doffoel-Hantz V; Meyer N; Bulai-Livideanu C; Viraben R; Maza A; Adoue D; Bedane C; Paul C J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1238-40. PubMed ID: 21054575 [No Abstract] [Full Text] [Related]
6. Rituximab for patients with refractory mucous membrane pemphigoid. Le Roux-Villet C; Prost-Squarcioni C; Alexandre M; Caux F; Pascal F; Doan S; Brette MD; Soued I; Gabison É; Aucouturier F; Letestu R; Laroche L; Bachelez H Arch Dermatol; 2011 Jul; 147(7):843-9. PubMed ID: 21422323 [TBL] [Abstract][Full Text] [Related]
20. [Mucous membrane pemphigoid. Guidelines for the diagnosis and treatment. Centres de référence des maladies bulleuses auto-immunes. Société Française de Dermatologie]. Bedane C; Prost C; Ingen-Housz-Oro S; Joly P; Bernard P; Ann Dermatol Venereol; 2011 Mar; 138(3):259-63. PubMed ID: 21397156 [No Abstract] [Full Text] [Related] [Next] [New Search]